Category: GLP-1 Receptor Agonists

GLP-1 receptor agonists are a class of medications used primarily in the treatment of type 2 diabetes and obesity. These drugs mimic the action of glucagon-like peptide-1 (GLP-1), a hormone that plays a key role in regulating blood sugar levels. By activating GLP-1 receptors, these drugs help increase insulin secretion in response to meals. It reduces glucagon release (which helps prevent the liver from producing too much glucose), and slow gastric emptying.

Key drugs in this class include liraglutide (Victoza, Saxenda), semaglutide (Ozempic, Wegovy), exenatide (Byetta), dulaglutide (Trulicity), and liraglutide (Saxenda). These medications offer additional benefits, such as weight loss and cardiovascular protection. It makes them important in managing both diabetes and obesity. GLP-1 receptor agonists are typically administered via injection, with some newer formulations available for weekly use, improving patient adherence and treatment outcomes.